ET-traps is a biotech venture that aims to develop novel therapeutic intervention in a host of different diseases associated with increased endothelin-1 levels. Numerous research has shown that increased endothelin-1 levels are a critical factor in the pathophysiology of these diseases. Our technology could potentially provide a unique treatment option in several areas of unmet medical need.
Get in touch
News about ET-traps
Entrepreneurship and innovation
Venturing forth: ET-traps
A biotech entrepreneurial weekend at Cambridge Judge Business School kickstarted a venture that seeks to tackle diabetes through a novel treatment.